Gadoxetate Disodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 564088

CAS#: 135326-22-6 (sodium)

Description: Gadoxetate Disodium is a liver-specific magnetic resonance imaging (MRI) contrast agent. Gadoxetate Disodium is preferentially taken up by normal functioning hepatocytes, so normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced.

Chemical Structure

img
Gadoxetate Disodium
CAS# 135326-22-6 (sodium)
Instruction

Theoretical Analysis

MedKoo Cat#: 564088
Name: Gadoxetate Disodium
CAS#: 135326-22-6 (sodium)
Chemical Formula: C23H28GdN3Na2O11
Exact Mass: 0.00
Molecular Weight: 725.717
Elemental Analysis: C, 38.07; H, 3.89; Gd, 21.67; N, 5.79; Na, 6.34; O, 24.25

Price and Availability

Size Price Availability Quantity
5mg USD 285 2 Weeks
10mg USD 450 2 Weeks
50mg USD 1250 2 Weeks
Bulk inquiry

Related CAS #: 770677-60-6   135326-22-6 (sodium)    

Synonym: Gd-EOB-DTPA; GdEOBDTPA; Gd EOB DTPA; Gadoxetate Disodium; ZK 139834; ZK-139834; ZK139834;

IUPAC/Chemical Name: Disodium 2-[[2-[bis(carboxylatomethyl)amino]-3-(4-ethoxyphenyl)propyl]-[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate gadolinium(3+)

InChi Key: DTWMOFPFJSYOOV-UHFFFAOYSA-L

InChi Code: InChI=1S/C23H30N3O11.Gd.2Na/c1-2-37-18-5-3-16(4-6-18)9-17(26(14-22(33)34)15-23(35)36)10-24(11-19(27)28)7-8-25(12-20(29)30)13-21(31)32;;;/h3-6,17H,2,7-15H2,1H3,(H,29,30)(H,33,34);;;/q;;2*+1/p-2

SMILES Code: CCOC1=CC=C(CC(CN(CC([O])=O)CCN(CC([O])=O)CC(O[Na])=O)N(CC([O])=O)CC(O[Na])=O)C=C1.[Gd]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2916.34.55.00

More Info: Gadoxetate Disodium is excreted in the bile, and it may be used to visualize the biliary system using MRI.

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 725.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fahlenkamp UL, Adams LC, Böker SM, Engel G, Huynh Anh M, Wagner M, Hamm B, Makowski MR. Feasibility of gadoxetate disodium enhanced 3D T1 MR cholangiography (MRC) with a specific inversion recovery prepulse for the assessment of the hepatobiliary system. PLoS One. 2018 Sep 5;13(9):e0203476. doi: 10.1371/journal.pone.0203476. eCollection 2018. PubMed PMID: 30183778; PubMed Central PMCID: PMC6124795.

2: Grazioli L, Faletti R, Frittoli B, Battisti G, Ambrosini R, Romanini L, Gatti M, Fonio P. Evaluation of incidence of acute transient dyspnea and related artifacts after administration of gadoxetate disodium: a prospective observational study. Radiol Med. 2018 Aug 6. doi: 10.1007/s11547-018-0927-y. [Epub ahead of print] PubMed PMID: 30084108.

3: Furlan A, Brancatelli G, Vilgrain V. Reply to "Oxaliplatin-Induced Liver Changes on Gadoxetate Disodium-Enhanced Liver MRI". AJR Am J Roentgenol. 2018 Aug;211(2):W134. doi: 10.2214/AJR.18.19786. PubMed PMID: 30036095.

4: Ünal E, Karcaaltincaba M. Oxaliplatin-Induced Liver Changes on Gadoxetate Disodium-Enhanced Liver MRI. AJR Am J Roentgenol. 2018 Aug;211(2):W133. doi: 10.2214/AJR.18.19722. PubMed PMID: 30036094.

5: Plaikner M, Kremser C, Zoller H, Steurer M, Glodny B, Jaschke W, Henninger B. Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase? Eur Radiol. 2018 Jul 19. doi: 10.1007/s00330-018-5616-7. [Epub ahead of print] PubMed PMID: 30027410.

6: Ringe KI, von Falck C, Raatschen HJ, Wacker F, Hinrichs J. Evaluation of transient respiratory motion artifact at gadoxetate disodium-enhanced MRI-Influence of different contrast agent application protocols. PLoS One. 2018 Jul 19;13(7):e0200887. doi: 10.1371/journal.pone.0200887. eCollection 2018. PubMed PMID: 30024930; PubMed Central PMCID: PMC6053213.

7: Chen MD, Zhang J, Yang GX, Lin JM, Feng YQ. [Differential diagnosis of hepatocellular carcinoma and hepatic hemangiomas based on radiomic features of gadoxetate disodium-enhanced magnetic resonance imaging]. Nan Fang Yi Ke Da Xue Xue Bao. 2018 Apr 20;38(4):428-433. Chinese. PubMed PMID: 29735443.

8: Lu CC, Chen WK, Chiang JH, Tsai YF, Juan YN, Lin PC, Tyan YS, Yang JS. cDNA Microarray Analysis and Influx Transporter OATP1B1 in Liver Cells After Exposure to Gadoxetate Disodium, a Gadolinium-based Contrast Agent in MRI Liver Imaging. In Vivo. 2018 May-Jun;32(3):677-684. PubMed PMID: 29695578; PubMed Central PMCID: PMC6000791.

9: Akai H, Yasaka K, Kunimatsu A, Nojima M, Inoue Y, Abe O, Ohtomo K, Kiryu S. The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green. Eur Radiol. 2018 Oct;28(10):4128-4133. doi: 10.1007/s00330-018-5403-5. Epub 2018 Apr 12. PubMed PMID: 29651770.

10: Allen BC, Ho LM, Jaffe TA, Miller CM, Mazurowski MA, Bashir MR. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma. AJR Am J Roentgenol. 2018 Jun;210(6):1266-1272. doi: 10.2214/AJR.17.18981. Epub 2018 Apr 9. PubMed PMID: 29629800.

11: Namimoto T, Shimizu K, Nakagawa M, Kikuchi Y, Kidoh M, Oda S, Nakaura T, Utsunomiya D, Yamashita Y. Reducing artifacts of gadoxetate disodium-enhanced MRI with oxygen inhalation in patients with prior episode of arterial phase motion: intra-individual comparison. Clin Imaging. 2018 Feb 2;52:11-15. doi: 10.1016/j.clinimag.2018.01.020. [Epub ahead of print] PubMed PMID: 29494992.

12: Tirumani SH, Jagannathan JP, Braschi-Amirfarzan M, Qin L, Balthazar P, Ramaiya NH, Shinagare AB. Value of hepatocellular phase imaging after intravenous gadoxetate disodium for assessing hepatic metastases from gastroenteropancreatic neuroendocrine tumors: comparison with other MRI pulse sequences and with extracellular agent. Abdom Radiol (NY). 2018 Sep;43(9):2329-2339. doi: 10.1007/s00261-018-1496-1. PubMed PMID: 29470627.

13: Min JH, Kim YK, Kang TW, Jeong WK, Lee WJ, Ahn S, Hwang NY. Artifacts during the arterial phase of gadoxetate disodium-enhanced MRI: Multiple arterial phases using view-sharing from two different vendors versus single arterial phase imaging. Eur Radiol. 2018 Aug;28(8):3335-3346. doi: 10.1007/s00330-018-5307-4. Epub 2018 Feb 15. PubMed PMID: 29450712.

14: Ringe KI, Luetkens JA, Fimmers R, Hammerstingl RM, Layer G, Maurer MH, Nähle CP, Michalik S, Reimer P, Schraml C, Schreyer AG, Stumpp P, Vogl TJ, Wacker FK, Willinek W, Kukuk GM. Characterization of Severe Arterial Phase Respiratory Motion Artifact on Gadoxetate Disodium-Enhanced MRI - Assessment of Interrater Agreement and Reliability. Rofo. 2018 Apr;190(4):341-347. doi: 10.1055/s-0044-100727. Epub 2018 Feb 15. PubMed PMID: 29448290.

15: Yamada A, Fujinaga Y, Suzuki T, Komatsu D, Kitoh Y, Iwadate Y, Nozaki A, Ueda K, Kadoya M. Quantitative estimation of progression of chronic liver disease using gadoxetate disodium-enhanced magnetic resonance imaging. Hepatol Res. 2018 Aug;48(9):735-745. doi: 10.1111/hepr.13069. Epub 2018 Mar 9. PubMed PMID: 29396898.

16: Gruber L, Rainer V, Plaikner M, Kremser C, Jaschke W, Henninger B. CAIPIRINHA-Dixon-TWIST (CDT)-VIBE MR imaging of the liver at 3.0T with gadoxetate disodium: a solution for transient arterial-phase respiratory motion-related artifacts? Eur Radiol. 2018 May;28(5):2013-2021. doi: 10.1007/s00330-017-5210-4. Epub 2017 Dec 20. PubMed PMID: 29264636.

17: Tillman BG, Gorman JD, Hru JM, Lee MH, King MC, Sirlin CB, Marks RM. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol. 2018 May;73(5):485-493. doi: 10.1016/j.crad.2017.11.013. Epub 2017 Dec 12. PubMed PMID: 29246586.

18: Well L, Weinrich JM, Adam G, Bannas P. Transient Severe Respiratory Motion Artifacts After Application of Gadoxetate Disodium: What We Currently Know. Rofo. 2018 Jan;190(1):20-30. doi: 10.1055/s-0043-120116. Epub 2017 Nov 20. Review. PubMed PMID: 29156475.

19: Kim B, Byun JH, Lee JH, Park BJ, Kwon HJ, Lee JH, Lee SJ, Won HJ, Shin YM, Kim PN. Imaging findings of primary hepatic angiosarcoma on gadoxetate disodium-enhanced liver MRI: comparison with hepatic haemangiomas of similar size. Clin Radiol. 2018 Mar;73(3):244-253. doi: 10.1016/j.crad.2017.09.015. Epub 2017 Oct 27. PubMed PMID: 29111237.

20: Fazeli Dehkordy S, Fowler KJ, Wolfson T, Igarashi S, Lamas Constantino CP, Hooker JC, Hong CW, Mamidipalli A, Gamst AC, Hemming A, Sirlin CB. Technical report: gadoxetate-disodium-enhanced 2D R2* mapping: a novel approach for assessing bile ducts in living donors. Abdom Radiol (NY). 2018 Jul;43(7):1656-1660. doi: 10.1007/s00261-017-1365-3. PubMed PMID: 29086007; PubMed Central PMCID: PMC6042650.